These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 23128322)

  • 1. Autologous stem cell transplantation for refractory or poor-risk relapsed Hodgkin's lymphoma: effect of the specific high-dose chemotherapy regimen on outcome.
    Nieto Y; Popat U; Anderlini P; Valdez B; Andersson B; Liu P; Hosing C; Shpall EJ; Alousi A; Kebriaei P; Qazilbash M; Parmar S; Bashir Q; Shah N; Khouri I; Rondon G; Champlin R; Jones RB
    Biol Blood Marrow Transplant; 2013 Mar; 19(3):410-7. PubMed ID: 23128322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin Lymphoma.
    Nieto Y; Thall PF; Ma J; Valdez BC; Ahmed S; Anderlini P; Popat U; Jones RB; Shpall EJ; Hosing C; Qazilbash M; Kebriaei P; Alousi A; Timmons M; Gulbis A; Myers A; Oki Y; Fanale M; Dabaja B; Pinnix C; Milgrom S; Champlin R; Andersson BS
    Biol Blood Marrow Transplant; 2018 Aug; 24(8):1602-1609. PubMed ID: 29501779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma.
    Nieto Y; Valdez BC; Thall PF; Jones RB; Wei W; Myers A; Hosing C; Ahmed S; Popat U; Shpall EJ; Qazilbash M; Gulbis A; Anderlini P; Shah N; Bashir Q; Alousi A; Oki Y; Fanale M; Dabaja B; Pinnix C; Champlin R; Andersson BS
    Cancer; 2016 Sep; 122(17):2680-8. PubMed ID: 27203405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas.
    Nieto Y; Valdez BC; Thall PF; Ahmed S; Jones RB; Hosing C; Popat U; Shpall EJ; Qazilbash M; Gulbis A; Anderlini P; Alousi A; Shah N; Bashir Q; Liu Y; Oki Y; Hagemeister F; Fanale M; Dabaja B; Pinnix C; Champlin R; Andersson BS
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):1914-20. PubMed ID: 26071868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose infusional gemcitabine combined with busulfan and melphalan with autologous stem-cell transplantation in patients with refractory lymphoid malignancies.
    Nieto Y; Thall P; Valdez B; Andersson B; Popat U; Anderlini P; Shpall EJ; Bassett R; Alousi A; Hosing C; Kebriaei P; Qazilbash M; Frazier E; Gulbis A; Chancoco C; Bashir Q; Ciurea S; Khouri I; Parmar S; Shah N; Worth L; Rondon G; Champlin R; Jones RB
    Biol Blood Marrow Transplant; 2012 Nov; 18(11):1677-86. PubMed ID: 22643322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autologous stem cell transplantation for Hodgkin's disease: busulfan, melphalan and thiotepa compared to a radiation-based regimen.
    Gutierrez-Delgado F; Holmberg L; Hooper H; Petersdorf S; Press O; Maziarz R; Maloney D; Chauncey T; Appelbaum F; Bensinger W
    Bone Marrow Transplant; 2003 Aug; 32(3):279-85. PubMed ID: 12858199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose busulfan, melphalan, and thiotepa followed by autologous peripheral blood stem cell transplantation in patients with aggressive lymphoma or relapsed Hodgkin's disease.
    Schiffman K; Buckner CD; Maziarz R; Maloney DG; Appelbaum FR; Press O; Gooley T; Holmberg L; Lilleby K; Clift R; Zuckerman N; Klarnet J; Weaver C; Chauncey T; Bensinger WI
    Biol Blood Marrow Transplant; 1997 Nov; 3(5):261-6. PubMed ID: 9450921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High dose chemotherapy and autologous stem cell transplantation for poor risk and recurrent non-Hodgkin's lymphoma: a single-center experience of 50 patients.
    Shim BY; Lee MA; Byun JH; Roh SY; Song CW; Park JN; Lee JW; Min WS; Hong YS; Kim CC
    Korean J Intern Med; 2004 Jun; 19(2):114-20. PubMed ID: 15366643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma.
    Rodriguez TE; Hari P; Stiff PJ; Smith SE; Sterrenberg D; Vesole DH
    Biol Blood Marrow Transplant; 2016 Aug; 22(8):1391-1396. PubMed ID: 27164062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autologous stem cell transplantation for non-Hodgkin's lymphoma: comparison of radiation-based and chemotherapy-only preparative regimens.
    Gutierrez-Delgado F; Maloney DG; Press OW; Golden J; Holmberg LA; Maziarz RT; Hooper H; Buckner CD; Appelbaum FR; Bensinger WI
    Bone Marrow Transplant; 2001 Sep; 28(5):455-61. PubMed ID: 11593318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic Analysis of Absolute Lymphocyte and Monocyte Counts after Autologous Stem Cell Transplantation in Children, Adolescents, and Young Adults with Refractory or Relapsed Hodgkin Lymphoma.
    Galvez-Silva J; Maher OM; Park M; Liu D; Hernandez F; Tewari P; Nieto Y
    Biol Blood Marrow Transplant; 2017 Aug; 23(8):1276-1281. PubMed ID: 28435146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GEM-P chemotherapy is active in the treatment of relapsed Hodgkin lymphoma.
    Hawkes EA; Barton S; Cunningham D; Peckitt C; Chua S; Wotherspoon A; Horwich A; Potter M; Ethel M; Dearden C; Chau I
    Ann Hematol; 2014 May; 93(5):827-34. PubMed ID: 24158386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Risk Factors and Long Term Survival Analysis of Patients With Primary Refractory Hodgkin Lymphoma Who Underwent High Dose Chemotherapy and Autologous Stem Cell Transplant.
    Akhtar S; Rauf MS; Elhassan TAM; Khan ZA; Elshenawy MA; Maghfoor I
    Transplant Cell Ther; 2023 Jul; 29(7):451.e1-451.e12. PubMed ID: 37031748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Positron emission tomography response at the time of autologous stem cell transplantation predicts outcome of patients with relapsed and/or refractory Hodgkin's lymphoma responding to prior salvage therapy.
    Devillier R; Coso D; Castagna L; Brenot Rossi I; Anastasia A; Chiti A; Ivanov V; Schiano JM; Santoro A; Chabannon C; Balzarotti M; Blaise D; Bouabdallah R
    Haematologica; 2012 Jul; 97(7):1073-9. PubMed ID: 22271893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pre-transplant FDG-PET-based survival model in relapsed and refractory Hodgkin's lymphoma: outcome after high-dose chemotherapy and auto-SCT.
    Akhtar S; Al-Sugair AS; Abouzied M; Alkadhi Y; Dingle M; Abdelsalam M; Soudy H; Darwish A; Eltigani A; Elhassan TA; Nabil-Ahmed M; Maghfoor I
    Bone Marrow Transplant; 2013 Nov; 48(12):1530-6. PubMed ID: 23749108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose chemotherapy in relapsed or refractory Hodgkin lymphoma patients: a reappraisal of prognostic factors.
    Cocorocchio E; Peccatori F; Vanazzi A; Piperno G; Calabrese L; Botteri E; Travaini L; Preda L; Martinelli G
    Hematol Oncol; 2013 Mar; 31(1):34-40. PubMed ID: 22473680
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcome analysis of high-dose chemotherapy and autologous stem cell transplantation in adolescent and young adults with relapsed or refractory Hodgkin lymphoma.
    Akhtar S; Rauf SM; Elhassan TA; Maghfoor I
    Ann Hematol; 2016 Sep; 95(9):1521-35. PubMed ID: 27376363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A multi-institutional analysis of peritransplantation radiotherapy in patients with relapsed/refractory Hodgkin lymphoma undergoing autologous stem cell transplantation.
    Milgrom SA; Jauhari S; Plastaras JP; Nieto Y; Dabaja BS; Pinnix CC; Smith GL; Allen PK; Lukens JN; Maity A; Oki Y; Fanale MA; Nasta SD
    Cancer; 2017 Apr; 123(8):1363-1371. PubMed ID: 27984652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravenous busulfan plus melphalan is a highly effective, well-tolerated preparative regimen for autologous stem cell transplantation in patients with advanced lymphoid malignancies.
    Kebriaei P; Madden T; Kazerooni R; Wang X; Thall PF; Ledesma C; Nieto Y; Shpall EJ; Hosing C; Qazilbash M; Popat U; Khouri I; Champlin RE; Jones RB; Andersson BS
    Biol Blood Marrow Transplant; 2011 Mar; 17(3):412-20. PubMed ID: 20674757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toxicities of busulfan/melphalan versus carboplatin/etoposide/melphalan for high-dose chemotherapy with stem cell rescue for high-risk neuroblastoma.
    Desai AV; Heneghan MB; Li Y; Bunin NJ; Grupp SA; Bagatell R; Seif AE
    Bone Marrow Transplant; 2016 Sep; 51(9):1204-10. PubMed ID: 27159174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.